Impact Factor
2.91
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.45
513 total citations
h5-index
30
h5 depth signal
Cited share
40.5%
152 of 375
Total citations
513
Citation footprint
Metric signal
2.54
External metric anchor
Self-citation
5.8%
30 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United Kingdom
1,649
United States
750
Australia
330
Canada
238
Netherlands
193
Citing Fields of Research
Sexually Transmitted Diseases
2,218
HIV
1,442
Antibiotic & Antibacterial Agents
236
Oncology
188
Psychiatry & Psychology
143
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
14,372
Articles tracked across the journal lifetime
Indexed publication set
375
152 cited publications
Last 12 months
136
11.3 publications/month
Open access share
33.8%
46 OA publications in the last year
Leading citing country
United Kingdom
1,649 citing publications
Leading citing field
Sexually Transmitted Diseases
2,218 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v74n1, Feb. 1998-
v74n1, Feb. 1998-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Sexually Transmitted Diseases
HIV
Broad Categories
Sexually Transmitted Diseases
HIV
MeSH Descriptors
HIV Infections
Sexually Transmitted Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1136/sextrans-2026-056993
Open DOI
Research news in clinical context
Naidoo et al. Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative tria...
03
DOI 10.1136/sextrans-2026-056931
Open DOI
Assessing interventions among men who have sex with men during the clade-IIb Mpox outbreak in Japan in 2023
04
DOI 10.1136/sextrans-2026-057145
Open DOI
Randomised trials of meningococcal B (4CMenB) vaccination for the prevention of gonorrhoea
05
DOI 10.1136/sextrans-2026-056974
Open DOI
Improved accuracy in detecting viable gastrointestinal Chlamydia trachomatis in women using multi-locus sequence typing
06
07
DOI 10.1136/sextrans-2026-057131
Open DOI
Neisseria gonorrhoeae antimicrobial resistance trends in Portugal over four decades, 1983–2025
08
DOI 10.1136/sextrans-2026-057137
Open DOI
Italian infectious diseases centres’ practices for Mycoplasma genitalium management: a nationwide PrIDE network survey
09
DOI 10.1136/sextrans-2026-057198
Open DOI
HIV breakthrough infection after 6 years of daily TDF/FTC oral PrEP with objectively documented optimal adherence
Oral Pre-Exposure Prophylaxis (PrEP) is highly effective for HIV prevention when adherence is optimal, with rare HIV breakthrough infections usually happening within 1–2 years since PrEP start. After 6 years of daily PrEP, routine HIV te...
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.